BLTE
USDBelite Bio Inc American Depositary Shares
即時價格
價格圖表
關鍵指標
市場指標
開盤
$114.150
最高
$114.440
最低
$112.000
交易量
0.08M
公司基本面
市值
4.0B
行業
生物科技
國家
United States
交易統計
平均交易量
0.07M
交易所
NCM
貨幣
USD
52週範圍
相關新聞
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
Benchmark analyst Bruce D. Jackson maintains Belite Bio with a Buy and raises the price target from $80 to $132.
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
